Home  /  Resource Library  /  Cost effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

Cost effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

Study examined the cost effectiveness of lenalidomide combined with rituximab compared to rituximab alone for treatment of relapsed follicular lymphoma.